References
- AbelZeta Pharma . AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China (2023). https://abelzeta.com/wp-content/uploads/2023/12/ABEL2023003-12-07-AZ-CAR031.pdf
- Elpiscience Biopharma . Elpiscience and Astellas Enter into Research Collaboration and License Agreement for Novel Bispecific Macrophage Engager (2023). www.elpiscience.com/upload/2023-12/170374035889778700.pdf
- ImmunoScape . ImmunoScape Partners with Singapore’s Experimental Drug Development Centre to Develop Novel T Cell Receptor-Based Therapeutics (2023). www.immunoscape.com/immunoscape-partners-singapores-experimental-drug-development-centre-to-develop-novel-t-cell-receptor-based-therapeutics/
- ImmunoScape . ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development (2023). www.immunoscape.com/immunoscape-and-mink-therapeutics-collaborate-to-accelerate-novel-tcr-identification-and-therapeutic-development/
- Atara Biotherapeutics . Atara Biotherapeutics Announces Closing of Expanded Global Tab-Cel® Partnership with Pierre Fabre Laboratories (2023). https://investors.atarabio.com/news-events/press-releases/detail/336/atara-biotherapeutics-announces-closing-of-expanded-global
- Charles River . Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening (2023). https://ir.criver.com/node/24936/pdf
- Taiwan Bio . Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant (2023). https://twbio-thera.com/language/en/taiwan-bio-and-tract-therapeutics-inc-announce-strategic-partnership-to-advance-a-novel-therapeutic-approach-for-preventing-rejection-in-solid-organ-transplant/
- Carisma Therapeutics . First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration (2023). https://ir.carismatx.com/node/9906/pdf
- Charles Rivers . Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration (2023). https://ir.criver.com/news-releases/news-release-details/charles-river-and-vertex-pharmaceuticals-reach-important
- Seattle Children’s . Seattle Children’s launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors (2023). www.seattlechildrens.org/media/press-releases/seattle-childrens-launches-brainchild-bio-to-accelerate-car-t-cell-therapies-for-children-with-brain-tumors/
- Allen Institute . Allen Institute, Chan Zuckerberg Initiative and the University of Washington announce the Seattle Hub for Synthetic Biology (2023). https://alleninstitute.org/division/seattle-hub-for-synthetic-biology/
- Obsidian Therapeutics . Obsidian Therapeutics Announces Positive Interim Top-Line Clinical Data for OBX-115 Engineered TIL Cell Therapy in Advanced or Metastatic Melanoma Post-Anti-PD1 Therapy (2023). https://obsidiantx.com/news-releases/obsidian-therapeutics-announces-positive-interim-top-line-clinical-data-for-obx-115-engineered-til-cell-therapy-in-advanced-or-metastatic-melanoma-post-anti-pd1-therapy/
- NCT05470283 . Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered with Membrane Bound IL15 Plus Acetazolamide in Adult Patients with Metastatic Melanoma (2023). https://clinicaltrials.gov/study/NCT05470283
- NCT06060613 . Safety and Efficacy of OBX-115 in Advanced Solid Tumors (2023). https://classic.clinicaltrials.gov/ct2/show/NCT06060613
- CARsgen . CARsgen’s CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia (2023). www.carsgen.com/en/news/2023124/
- NCT05838131 . Study of CT071 Injection in RRMM or PPCL (2023). https://clinicaltrials.gov/study/NCT05838131?term=NCT05838131
- CARsgen . CARsgen’s CT011 achieves IND clearance from the NMPA for the GPC3-positive stage IIIa hepatocellular carcinoma at high risk of recurrence after surgical resection (2023). www.carsgen.com/en/news/20240115/
- Chiesi . Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa (2023). www.chiesi.com/en/global-rare-diseases-fda-approval-filsuvez-epidermolysis-bullosa/
- bluebird bio . bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (2023). https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-fda-approval-lyfgeniatm-lovotibeglogene
- US FDA . FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease (2023). www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
- bluebird bio . bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events (2023). https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-details-plans-commercial-launch-lyfgeniatm-gene
- Vertex Pharmaceuticals . Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease (2023). https://news.vrtx.com/node/31706/pdf
- AstraZeneca . AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases (2023). www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html
- bluebird bio . bluebird bio, Inc. Announces Pricing of $125 Million Public Offering of Common Stock (2023). https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-inc-announces-pricing-125-million-public-offering
- FujiFilm . Fujifilm to Invest USD 200 Million to Expand Cell Therapy Development and Manufacturing Capabilities (2023). www.fujifilm.com/pt/en/news/hq/10925
- PR Newswire . Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform (2023). www.prnewswire.com/news-releases/shinobi-therapeutics-launches-with-completion-of-51m-series-a-to-advance-hypoimmune-ips-t-cell-therapy-platform-302012188.html